Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma

• Verfasst von: Giesel, Frederik L. [VerfasserIn]
• Verfasst von: Will, Leon [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Verfasst von: Haberkorn, Uwe [VerfasserIn]
• Titel: Intra-individual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma
• Titelzusatz: a pilot study
• Verf.angabe: Frederik Giesel, Leon Will, Ismaheel Lawal, Thabo Lengana, Clemens Kratochwil, Mariza Vorster, Oliver Neels, Florette Reyneke, Uwe Haberkon, Klaus Kopka, and Mike Sathekge
• Jahr: 2018
• Umfang: 5 S.
• Fussnoten: Published online: December 21, 2017 ; Im Titel falsche Schreibweise von Uwe Haberkorn ; Im Titel ist "18" hochgestellt ; Gesehen am 21.06.2018
• Titel Quelle: Enthalten in: Journal of nuclear medicine technology
• Ort Quelle: New York, NY : Soc., 1973
• Jahr Quelle: 2018
• Band/Heft Quelle: 59(2018), 7, Seite 1076-1080
• ISSN Quelle: 1535-5675
• DOI: doi:10.2967/jnumed.117.204669
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 18F-DCFPyL
• Sach-SW: 18F-PSMA-1007
• Sach-SW: Molecular Imaging
• Sach-SW: Oncology: GU
• Sach-SW: PET/CT
• Sach-SW: Prostate carcinoma
• Sach-SW: PSMA
• K10plus-PPN: 157644404X

Abstract

Introduction: The introduction of 18F-labelled prostate-specific membrane antigen (PSMA) targeted positron emission tomography/computed-tomography (PET/CT) tracers, firstly 18F-DCFPyL and more recently 18F-PSMA-1007, have demonstrated promising results for the diagnostic workup of prostate cancer (PCa). This clinical study presents an intra-individual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL versus 18F-PSMA-1007. Methods: Twelve prostate cancer patients, drug naive or prior to surgery, received similar activities of about 250 MBq 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h p.i. in the same PET/CT-scanner using the same reconstruction-algorithm. Normal organ biodistribution and tumor uptakes were quantified using SUVmax. Results: PSMA-positive lesions were detected in twelve out of twelve PCa patients. Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the identical lesions. No statistical significance could be observed when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases and bone metastases. With regard to normal organs, 18F-DCFPyL presented statistically significant higher uptake in kidneys, urinary bladder and lacrimal gland. Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007 resulting in identical clinical findings for the evaluated routine situations. Non-urinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph-node metastasis in selective patients; the lower hepatic background might favor 18F-DCFPyL in very late stages when rare cases of liver metastases can occur.